Preview

Вестник трансплантологии и искусственных органов

Расширенный поиск

Цитомегаловирусная инфекция после трансплантации почки: реальные достижения и перспективы изучения патогенеза, профилактики и лечения

https://doi.org/10.15825/1995-1191-2019-3-151-165

Полный текст:

Аннотация

Цитомегаловирусная (ЦМВ) инфекция играет важную роль в клинической трансплантологии, поскольку повышает риск развития осложнений, потери трансплантатов, смерти пациентов. Вирус обладает как прямыми (непосредственное повреждение органов и тканей), так и непрямыми иммуномодулирующими эффектами. Международная группа экспертов на основании проведенных исследований разработала общие принципы ведения ЦМВ-инфекции после трансплантации. В статье рассматриваются факторы риска, патогенетические механизмы развития ЦМВ-инфекции после трансплантации почки, принципы диагностики, лечения и профилактики данного осложнения, пути преодоления лекарственной устойчивости вируса. Обсуждаются перспективы применения иммунологического мониторинга, новых противовирусных препаратов, а также возможность использования ЦМВ-вакцин, T-клеточной терапии, иммуносупрессантов – ингибиторов mTOR, обладающих противовирусным действием.

Об авторе

Е. И. Прокопенко
ГБУЗ МО «Московский областной научно-исследовательский клинический институт имени М.Ф. Владимирского»
Россия
Прокопенко Елена Ивановна. Адрес: 129110, Москва, ул. Щепкина, д. 61/2. Тел. (495) 684-57-91.


Список литературы

1. Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol. 2001; 12 (4): 848–855. PMID: 11274248.

2. Humar A, Snydeman D; AST Infectiuos Diseases Community of Pratice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant. 2009; 9 Suppl 4: S78–86. doi: 10.1111/j.1600-6143.2009.02897.x.

3. Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA et al. Kidney Disease: Improving Global Outcomes. Clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney International. 2010; 77 (4): 299–311. doi: 10.1038/ ki.2009.377.

4. Прокопенко ЕИ, Щербакова ЕО, Ватазин АВ, Русанова ЕВ, Степанов ВА, Панкратенко ТЕ и др. Инфицированность герпетическими вирусами и пневмоцистами сотрудников центра трансплантации и диализа. Альманах клинической медицины. 2012; 27: 39–46. Prokopenko EI, Shcherbakova EO, Vatazin AV, Rusanova EV, Stepanov VA, Pankratenko TE i dr. Inficirovannost’ gerpeticheskimi virusami i pnevmocistami sotrudnikov centra transplantacii i dializa. Al’manah klinicheskoj mediciny. 2012; 27: 39–46.

5. Goodrum F, Caviness K, Zagallo P. Human cytomegalovirus persistence. Cell Microbiol. 2012; 14 (5): 644– 655. doi: 10.1111/j.1462-5822.2012.01774.x.

6. Britt W. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr Top Microbiol Immunol. 2008; 325: 417– 470. PMID: 18637519.

7. Streblow DN, Dumortier J, Moses AV, Orloff SL, Nelson JA. Mechanisms of cytomegalovirus accelerated vascular disease: induction of paracrine factors that promote angiogenesis and wound healing. Curr Top Microbiol Immunol. 2008; 325: 397–415. PMID: 18637518.

8. Requião-Moura LR, Carvalho de Matos AC, PachecoSilva A. Cytomegalovirus infection in renal transplantation: clinical aspects, management and the perspectives. Einstein. 2015; 13 (1): 142–148. doi: 10.1590/ S1679-45082015RW3175.

9. Selvey LA, Lim WH, Boan P, Swaminathan R, Slimings C, Harrisonet AE et al. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience. BMC Infect Dis. 2017; 17: 501– 509. doi: 10.1186/s12879-017-2599-y.

10. Stern M, Hirsch H, Cusini A, van Delden C, Manuel O, Meylan P et al. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation. 2014; 98: 1013–1018. doi: 10.1097/ TP.0000000000000160.

11. Kotton CN. CMV: prevention, diagnosis and therapy. Am J Transplant. 2013; 13 (Suppl 3): 24–40. quiz 40. doi: 10.1111/ajt.12006.

12. López-Oliva MO, Flores J, Madero R, Escuin F, Santana MJ, Bellón T et al. Cytomegalovirus infection after kidney transplantation and long-term graft loss. Nefrologia. 2017; 37 (5): 515–525. doi: 10.1016/j.nefro.2016.11.018.

13. Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017; 64: 87–91. doi: 10.1093/cid/ciw668.

14. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006; 6: 262–274. doi: 10.1111/j.16006143.2005.01207.x.

15. Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, Humar A; The Transplantation Society International CMV Consensus Group. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018; 102 (6): 900–931. doi: 10.1097/TP.0000000000002191.

16. Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol. 2005; 16: 1758–1774. doi: 10.1681/ASN.2004121113.

17. Bae SH, Chung BH, Park YK, Jo K, Yang CW, Kim Y-S, Choi BS. Cytomegalovirus induced interstitial nephritis and ureteral stenosis in renal transplant recipient. Korean J Intern Med. 2012; 27: 470–473. doi: 10.3904/ kjim.2012.27.4.470.

18. Reischig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation. 2009; 87: 436–444. doi: 10.1097/TP.0b013e318192ded5.

19. Bosch W, Heckman MG, Pungpapong S, Diehl NN, Shalev JA, Hellinger WC et al. Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation. Transplantation. 2012; 93: 723–728. doi: 10.1097/TP.0b013e3182472876.

20. Puliti Reigada CH, de Ataide EC, de Almeida Prado Mattosinho T, Boin IFSF. Hepatic artery thrombosis after liver transplantation: five-year Experience at the state university of Campinas. Transplant Proc. 2017; 49 (4): 867–870. doi: 10.1016/j.transproceed.2017.01.056.

21. Sobieszczańska-Małek M, Korewicki J, Komuda K, Karczmarz M, Szymańska S, Cicha-Mikołajczyk A et al. Heart transplantation and risk of cardiac vasculopathy development: what factors are important? Ann Transplant. 2017 17; 22: 682–688. PMID: 29146891.

22. Paraskeva M,Bailey M, LevveyBJ,GriffithsAP,Kotsimbos TC, Williams TP et al. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant. 2011; 11 (10): 2190–2196. doi: 10.1111/j.1600-6143.2011.03663.x.

23. Reischig T, Kacer M, Hruba P, Jindra P, Hes O, Lysak D et al. The impact of viral load and time to onset of cytomegalovirus replication on long-term graft survival after kidney transplantation. Antivir Ther. 2017; 22 (6): 503–513. doi: 10.3851/IMP3129.

24. Martin-Gandul C, Mueller NJ, Pascual M, Manuel O et al. The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation. Am J Transplant. 2015; 15 (12): 3024–3040. doi: 10.1111/ajt.13486.

25. Yong MK, Slavin MA, Kontoyiannis DP. Invasive fungal disease and cytomegalovirus infection: is there an association? Curr Opin Infect Dis. 2018; 31 (6): 481– 489. doi: 10.1097/QCO.0000000000000502.

26. Kim JM, Lee SK, Kim SJ, Joh JW, Kwon CH, Choe YH et al. Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia. Transplant Proc. 2010; 42 (3): 895–899. doi: 10.1016/j.transproceed.2010.02.042.

27. Komorowska-Jagielska K, Heleniak Z, DębskaŚlizień A. Cytomegalovirus Status of Kidney Transplant Recipients and Cardiovascular Risk. Transplant Proc. 2018; 50 (6): 1868–1873. doi: 10.1016/j.transproceed.2018.03.126.

28. Santos AH Jr, Chen C, Casey MJ, Womer KL, Wen X. New-onset diabetes after kidney transplantation: can the risk be modified by choosing immunosuppression regimen based on pretransplant viral serology? Nephrol Dial Transplant. 2018; 33 (1): 177–184. doi: 10.1093/ ndt/gfx281.

29. Koch S, Larbi A, Ozcelik D, Solana R, Gouttefangeas C, Attig S et al. Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann N Y Acad Sci. 2007; 1114: 23–25. doi: 10.1196/annals.1396.043.

30. Toupance O, Bouedjoro-Camus MC, Carquin J, Novella JL, Lavaud S, Wynckel A et al. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses. Transpl Int. 2000; 13 (6): 413–419. PMID: 11140239.

31. Hasanzamani B, Hami M, Zolfaghari V, Torkamani M, Ghorban Sabagh M, Ahmadi Simab S. The effect of cytomegalovirus infection on acute rejection in kidney transplanted patients. J Renal Inj Prev. 2016; 5 (2): 85–88. doi: 10.15171/jrip.2016.18.

32. Bachelet T, Couzi L, Pitard V, Sicard X, Rigothier C, Lepreux S. et al. Cytomegalovirus-responsive γδ T cells: novel effector cells in antibody-mediated kidney allograft microcirculation lesions. J Am Soc Nephrol. 2014; 25 (11): 2471–2482. doi: 10.1681/ASN.2013101052.

33. Sagedal S, Nordal KP, Hartmann A, Sund S, Scott H, Degré M et al. The impact of cytomegalovirus infection and disease onrejection episodes in renal allograft recipients. Am J Transplant. 2002; 2: 850–856. PMID: 12392291.

34. Burgan H, Gosteli G, Giovannini M, Lienhard R, Clerc O. Very-late-onset cytomegalovirus disease: a case-report and review of the literature. BMC Res Notes. 2017; 10 (1): 210. doi: 10.1186/s13104-0172532-x.

35. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant. 2009; 9 (Suppl 4): S78–86. doi: 10.1111/j.1600-6143.2009.02897.x.

36. Asberg A, Jardine AG, Bignamini AA, Rollag H, Pescovitz MD, Gahlemann CC et al.; VICTOR Study Group. Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. Am J Transplant. 2010; 10 (8): 1881–1888. doi: 10.1111/j.1600-6143.2010.03114.x.

37. Roayaie S, Sheiner PA, Emre S, Guy S, Schwartz ME, Boros P et al. Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients. Mediators Inflamm. 2000; 9 (3–4): 141–146. doi: 10.1080/09629350020002877.

38. Limaye AP, La Rosa C, Longmate J, Diamond DJ. Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. Transplantation. 2016; 100 (1): 210–216. doi: 10.1097/TP.0000000000000816.

39. Moorman NJ, Shenk T. Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication. J Virol. 2010; 84 (10): 5260–5269. doi: 10.1128/ JVI.02733-09.

40. Clippinger AJ, Maguire TG, Alwine JC. The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection. J Virol. 2011; 85 (8): 3930–3939. doi: 10.1128/JVI.01913-10.

41. Poglitsch M, Weichhart T, Hecking M, Werzowa J, Katholnig K, Antlanger M et al. CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages. Am J Transplant. 2012; 12 (6): 1458–1468. doi: 10.1111/j.16006143.2012.04002.x.

42. Fernández-Ruiz M, Corrales I, Arias M, Campistol JM, Giménez E, Crespo J et al. Association between individual and combined SNPs in genes related to innate immunity and incidence of CMV infection in seropositive kidney transplant recipients. Am J Transplant. 2015; 15 (5): 1323–1335. doi: 10.1111/ajt.13107.

43. Kaminski H, Fishman JA. The сell biology of сytomegalovirus: implications for transplantation. Am J Transplant. 2016; 16 (8): 2254–2269. doi: 10.1111/ ajt.13791.

44. Hill P, Cross NB, Barnett AN, Palmer SC, Webster AC. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. Cochrane Database Syst Rev. 2017; 1: CD004759. doi: 10.1002/14651858.CD004759.

45. Gangopadhyay S, Rampersaud H, Pelletier JP, Herman L, Goldstein S, Upadhyay K. Cytomegalovirus transmission in pediatric renal transplant recipients during the window period. Pediatr Transplant. 2016; 20 (1): 172–177. doi: 10.1111/petr.12654.

46. Delforge ML, Desomberg L, Montesinos I. Evaluation of the new LIAISON(®) CMV IgG, IgM and IgG Avidity II assays. J Clin Virol. 2015; 72: 42–45. doi: 10.1016/j.jcv.2015.09.002.

47. Seed CR, Piscitelli LM, Maine GT, Lazzarotto T, Doherty K, Stricker R et al. Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood. Transfusion. 2009; 49: 134–145. doi: 10.1111/j.15372995.2008.01932.x.

48. Humar A, Mazzulli T, Moussa G Razonable RR, Paya CV, Pescovitz MD et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R− transplant recipients. Am J Transplant. 2005; 5: 1065–1070. doi: 10.1111/j.1600-6143.2005.00797.x.

49. Pillay D, Ali AA, Liu SF, Kops E, Sweny P, Griffiths PD. The prognostic significance of positive CMV cultures during surveillance of renal transplant recipients. Transplantation. 1993; 56: 103–108. PMID: 8392760.

50. Dioverti MV, Lahr B, Razonable RR. Treatment of cytomegalovirus infection and disease pre- and post-quantitative nucleic acid test standardization: does use of a more sensitive assay lead to longer treatment duration? Clin Transplant. 2016; 30 (2): 154–160. doi: 10.1111/ ctr.12671.

51. Mills AM, Guo FP, Copland AP, Pai RK, Pinsky BA. A comparison of CMV detection in gastrointestinal mucosal biopsies using immunohistochemistry and PCR performed on formalin-fixed, paraffin-embedded tissue. Am J Surg Pathol. 2013; 37 (7): 995–1000. doi: 10.1097/PAS.0b013e31827fcc33.

52. Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2010; 10: 157–161. doi: 10.1111/j.1600-6143.2009.02861.x.

53. Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J Infect Dis. 2004; 190: 1076–1083. doi: 10.1086/422327.

54. Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis. 2000; 2: 112–117. PMID: 11429021.

55. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med. 1999; 340: 1462–1470. doi: 10.1056/ NEJM199905133401903.

56. Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG et al. Extended valganciclovir prophylaxis in D+/R– kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation. 2010; 90 (12): 1427–1431. PMID: 21197713.

57. Večerić-Haler Ž, Bizjak B, Romozi K, Arnol M. Expanded valganciclovir prophylaxis in kidney transplant recipients is associated with lower incidence of cytomegalovirus infection. Clin Nephrol. 2017 Suppl 1; 88 (13): 126–130. doi: 10.5414/CNP88FX27.

58. Прокопенко ЕИ, Щербакова ЕО, Ватазин АВ, Янковой АГ, Пасов СА, Степанов ВА и др. Результаты профилактики цитомегаловирусной инфекции валганцикловиром у пациентов с трансплантированной почкой. Клиническая нефрология. 2013; 5: 37–41. Prokopenko EI, Shcherbakova EO, Vatazin AV, Jankovoj AG, Pasov SA, Stepanov VA i dr. Rezul’taty profilaktiki citomegalovirusnoj infekcii valganciklovirom u pacientov s transplantirovannoj pochkoj. Klinicheskaja nefrologija. 2013; 5: 37–41.

59. Садовский ДН, Калачик ОВ, Юнис Н, Лавринюк РП, Амвросьева ТВ, Гринкевич ПИ и др. Цитомегаловирусная инфекция при трансплантации почки. Медицинский журнал.2012; 4 (42): 85–88. Sadovskij DN, Kalachik OV, Junis N, Lavrinjuk RP, Amvros’eva TV, Grinkevich PI i dr. Citomegalovirusnaja infekcija pri transplantacii pochki. Medicinskij zhurnal. 2012; 4 (42): 85–88.

60. Liang X, Famure O, Li Y, Kim SJ. Incidence and risk factors for leukopenia in kidney transplant recipients receiving valganciclovir for cytomegalovirus prophy laxis. Prog Transplant. 2018; 28 (2): 124–133. doi: 10.1177/1526924818765798.

61. Lúcia M, Crespo E, Cruzado JM, Grinyó JM, Bestard O. Human CMV-specific T-cell responses in kidney transplantation; toward changing current risk-stratification paradigm. Transpl Int. 2014; 27 (7): 643–656. doi: 10.1111/tri.12318.

62. Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis. 2001; 184: 1461–1464. doi: 10.1086/324516.

63. Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010; 10: 1228–1237. doi: 10.1111/j.16006143.2010.03074.x.

64. JamalAJ,Husain S,Li Y,FamureO,KimSJ. Risk factors for late-onset cytomegalovirus infection or disease in kidney transplant recipients. Transplantation. 2014; 97 (5): 569–575. doi: 10.1097/01.tp.0000438197.38413.f2.

65. Lisboa LF, Preiksaitis JK, Humar A, Kumar D. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients. Transplantation. 2011; 92: 1063– 1068. doi: 10.1097/TP.0b013e31822fa4b7.

66. Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. Transplantation. 2011; 91: 251–255. doi: 10.1097/ TP.0b013e318200b9f0.

67. Atabani SF, Smith C, Atkinson C, Aldridge RW, Rodriguez-Perálvarez M, Rolando N et al. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant. 2012; 12: 2457–2464. doi: 10.1111/j.16006143.2012.04087.x.

68. Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation. 2012; 93: 61–68. doi: 10.1097/TP.0b013e318238dab3.

69. Rawal BB, Shadrou S, Abubacker F, Ghahramani N. A Systematic Review and Metaanalysis of Prophylactic versus Pre-emptive Strategies for Preventing Cytomegalovirus Infection in Renal Transplant Recipients. Int J Organ Transplant Med. 2012; 3 (1): 10–17. PMCID: PMC4089275.

70. Brennan DC, Legendre C, Patel D, Mange K, Wiland A, McCague K, Shihab FS. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant. 2011; 11 (11): 2453–2462. doi: 10.1111/j.1600-6143.2011.03674.x.

71. Su L, Tam N, Deng R, Chen P, Li H, Wu L et al. Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis. Int Urol Nephrol. 2014; 46: 2035–2044. doi: 10.1007/s11255-014-0783-1.

72. Radtke J, Dietze N, Spetzler VN, Fischer L, Achilles EG, Li J et al. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid. Transpl Infect Dis. 2016; 18: 79–88. doi: 10.1111/tid.12494.

73. Sheng L, Jun S, Jianfeng L, Lianghui G. The effect of sirolimus-based immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation. Clin Transplant. 2015; 29: 555– 559. doi: 10.1111/ctr.12552.

74. Kobashigawa J, Ross H, Bara C, Delgado JF, Dengler T, Lehmkuhl HB et al. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. Transpl Infect Dis. 2013; 15: 150–162. doi: 10.1111/tid.12007.

75. Rittà M, Costa C, Solidoro P, Sidoti F, Libertucci D, Boffini Mt al. Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection. Antiviral Res. 2015; 113: 19–26. doi: 10.1016/j.antiviral.2014.10.016.

76. Strueber M, Warnecke G, Fuge J, Simon AR, Zhang R, Welte T et al. Everolimus versus mycophenolate mofetil de novo after lung transplantation: a prospective, randomized, open-label trial. Am J Transplant. 2016; 16: 3171–3180. doi: 10.1111/ajt.13835.

77. Hocker B, Zencke S, Pape L, Krupka K, Köster L, Fichtner A et al. Impact of everolimus and low-dose cyclosporin on cytomegalovirus replication and disease in pediatric renal transplantation. Am J Transplant. 2016; 16: 921–929. doi: 10.1111/ajt.13649.

78. Mallat SG, Tanios BY, Itani HS, Lotfi T, McMullan C, Gabardi S et al. CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR InhibitorBased Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials. Clin J Am Soc Nephrol. 2017; 12 (8): 1321–1336. doi: 10.2215/CJN.13221216.

79. Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y et al. Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. J Am Soc Nephrol. 2018; 29 (7): 1979–1991. doi: 10.1681/ ASN.2018010009.

80. Havenith SH, Yong SL, van Donselaar-van der Pant KA, van Lier RA, ten Berge IJ, Bemelman F. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients. Transplantation. 2013; 95 (1): 184–191. doi: 10.1097/ TP.0b013e318276a1ef.

81. Andrassy J, Hoffmann VS, Rentsch M, Stangl M, Habicht A, Meiser B et al. Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitorbased immunosuppression? a systematic review and meta-analysis. Transplantation. 2012; 94 (12): 1208– 1217. doi: 10.1097/TP.0b013e3182708e56.

82. Cervera C, Cofan F, Hernandez C, Soy D, Marcos MA, Sanclemente G et al. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis. Transpl Int. 2016; 29 (11): 1216–1225. doi: 10.1111/tri.12848.

83. Felipe C, Tedesco-Silva H, Ferreira Brigido A, Bessa A, Ruppel P, Hiramoto L et al. Cost-Effectiveness analysis of everolimus versus mycophenolate in kidney transplant recipients receiving no pharmacological prophylaxis for cytomegalovirus infection: a short-term pharmacoeconomic evaluation (12 months). Value Health Reg Issues. 2017; 14: 108–115. doi: 10.1016/j. vhri.2017.08.009.

84. Asberg A, Humar A, Jardine AG, Rollag H, Pescovitz MD, Mouas H et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant. 2009; 9: 1205–1213. doi: 10.1111/j.16006143.2009.02617.x.

85. Официальная инструкция к лекарственному препарату Цимевен® (Cymevene®); https://www.rlsnet.ru/tn_index_id_95612.htm.

86. Young PG, Rubin J, Angarone M, Flaherty J, Penugonda S, Stosor V, Ison MG et al. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study. Transpl Infect Dis. 2016; 18 (3): 390–395. doi: 10.1111/ tid.12537.

87. Ar MC, Ozbalak M, Tuzuner N, Bekoz H, Ozer O, Ugurlu K et al. Severe bone marrow failure due to valganciclovir overdose after renal transplantation from cadaveric donors: four consecutive cases. Transplant Proc. 2009; 41 (5): 1648–1653. doi: 10.1016/j.transproceed.2009.02.093.

88. Asberg A, Humar A, Rollag H, Jardine AG, Kumar D, Aukrust P et al. Lessons learned from a randomized study of oral valganciclovir versus parenteral ganciclovir treatment of cytomegalovirus disease in solid organ transplant recipients: the VICTOR trial. Clin Infect Dis. 2016; 62: 1154–1160. doi: 10.1093/cid/ciw084.

89. Sullivan T, Brodginski A, Patel G, Huprikar S et al. The role of secondary cytomegalovirus prophylaxis for kidney and liver transplant recipients. Transplantation. 2015; 99: 855–859. doi: 10.1097/ TP.0000000000000386.

90. Natori Y, Humar A, Husain S, Rotstein C, Renner E, Singer L et al. Recurrence of CMV infection and the effect of prolonged antivirals in organ transplant recipients. Transplantation. 2017; 101: 1449–1454. doi: 10.1097/TP.0000000000001338.

91. Gardiner BL, Chow JK, Price LL, Nierenberg NE, Kent DM, Snydman DR. Role of secondary prophylaxis with valganciclovir in the prevention of recurrent cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis. 2017; 65: 2000–2007. doi: 10.1093/cid/cix696.

92. Myhre HA, Haug Dorenberg D, Kristiansen KI, Rollag H, Leivestad T, Asberg A et al. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation. 2011; 92: 217–223. doi: 10.1097/ TP.0b013e31821fad25.

93. Young PG, Rubin J, Angarone M, Flaherty J, Penugonda S, Stosor V et al. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study. Transpl Infect Dis. 2016; 18: 390–395. doi: 10.1111/tid.12537.

94. Boivin G, Goyette N, Farhan M, Ives J, Elston R. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. J Clin Virol. 2012; 53: 208–213. doi: 10.1016/j.jcv.2011.12.019.

95. Komatsu TE, Pikis A, Naeger LK, Harrington PR. Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathways. Antiviral Res. 2014; 101: 12–25. doi: 10.1016/j.antiviral.2013.10.011.

96. Campos AB, Ribeiro J, Boutolleau D, Sousa H. Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art. Rev Med Virol. 2016; 26: 161–182. doi: 10.1002/rmv.1873.

97. Fisher CE, Knudsen JL, Lease ED, Jerome KR, Rakita RM, Boeckh M et al. Risk factors and outcomes of ganciclovir resistant cytomegalovirus infection in solid organ transplant recipients. Clin Infect Dis. 2017; 65: 57–63. doi: 10.1093/cid/cix259.

98. Gracia-Ahufinger I, Gutierrez-Aroca J, Cordero E, Vidal E, Cantisán S, del Castillo D et al. Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducingmutations. Transplantation. 2013; 95: 1015–1020. doi: 10.1097/TP.0b013e31828555ac.

99. Myhre HA, Haug Dorenberg D, Kristiansen KI, Rollag H, Leivestad T, Asberg A et al. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation. 2011; 92: 217–223. doi: 10.1097/ TP.0b013e31821fad25.

100. Avery RK, Arav-Boger R, Marr KA, Kraus E, Shoham S, Lees L et al. Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection. Transplantation. 2016; 100: e74–e80. doi: 10.1097/TP.0000000000001418.

101. Minces LR, Nguyen MH, Mitsani D, Shields RK, Kwak EJ, Silveira FP et al. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens. Antimicrob Agents Chemother. 2014; 58: 128–135. doi: 10.1128/ AAC.00561-13.

102. Patel SJ, Kuten SA, Knight RJ, Hong DM, Gaber AO et al. Resolution of mild ganciclovirresistant cytomegalovirus disease with reduced-dose cidofovir and CMV-hyperimmune globulin. J Transplant. 2014; 2014: 342319. doi: 10.1155/2014/342319.

103. Bonatti H, Sifri CD, Larcher C, Schneeberger S, Kotton C, Geltner C et al. Use of cidofovir for cytomegalovirus disease refractory to ganciclovir in solid organ recipients. Surg Infect (Larchmt). 2017; 18 (2): 128–136. doi: 10.1089/sur.2015.266.

104. Strasfeld L, Lee I, Villano S, Villano S, Chou S. Virologic characterization of multi-drugresistant cytome galovirus infection in two transplant recipients treated with maribavir. J Infect Dis. 2010; 202: 104–108. doi: 10.1086/653122.

105. Chou S, Ercolani RJ, Sahoo MK, Lefterova MI, Strasfeld LM, Pinsky BA. Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. Antimicrob Agents Chemother. 2014; 58 (8): 4697–4702. doi: 10.1128/AAC.03214-14.

106. Kaul DR, Stoelben S, Cober E, Ojo T, Sandusky E, Lischka P. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011; 11 (5): 1079–1084. doi: 10.1111/j.16006143.2011.03530.x.

107. Macesic N, Langsford D, Nicholls K, Hughes P, Gottlieb DJ, Clancy L et al. Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient. Am J Transplant. 2015; 15 (3): 827–832. doi: 10.1111/ajt.13023.

108. Aiba N, Shiraki A, Yajima M, Oyama Y, Yoshida Y, Ohno A et al. Interaction of Immunoglobulin with Cytomegalovirus-Infected Cells. Viral Immunol. 2017; 30 (7): 500–507. doi: 10.1089/vim.2016.0151.

109. Sabé N, González-Costello J, Rama I, Niubó J, Bodro M, Roca J et al. Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors. Transpl Int. 2012; 25 (7): e78–82. doi: 10.1111/j.14322277.2012.01489.x.

110. Morita S, Shinoda K, Tamaki S, Kono H, Asanuma H, Nakagawa K, Oya M. Successful low-dose leflunomide treatment for ganciclovir-resistant cytomegalovirus infection with high-level antigenemia in a kidney transplant: A case report and literature review. J Clin Virol. 2016; 82: 133–138. doi: 10.1016/j.jcv.2016.07.015.

111. Drouot E, Piret J, Boivin G. Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus. Antivir Ther. 2016; 21 (6): 535–539. doi: 10.3851/IMP3028.

112. Aguilar C, Husain S, Lortholary O. Recent advances in understanding and managing infectious diseases in solid organ transplant recipients. F1000Res. 2018 May 24; 7. pii: F1000 Faculty Rev-661. doi: 10.12688/ f1000research.14262.1.

113. Lee H, Park KH, Ryu JH, Choi AR, Yu JH, Lim J et al. Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients. PLoS One. 2017 Dec 12; 12 (12): e0189488. doi: 10.1371/journal. pone.0189488.

114. Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013; 56 (6): 817–824. doi: 10.1093/cid/cis993.

115. Kumar D, Mian M, Singer L, Humar A. An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation. Am J Transplant. 2017; 17 (9): 2468–2473. doi: 10.1111/ajt.14347.

116. Vial R, Zandotti C, Alain S, Decourt A, Jourde-Chiche N, Purgus R et al. Brincidofovir use after foscarnet crystal nephropathy in a kidney transplant recipient with multiresistant cytomegalovirus infection. Case Rep Transplant. 2017; 2017: 3624146. doi: 10.1155/2017/3624146.

117. Winston DJ, Saliba F, Blumberg E, Abouljoud M, Garcia-Diaz JB, Goss JA et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant. 2012; 12 (11): 3021–3030. doi: 10.1111/j.1600-6143.2012.04231.x.

118. Alain S, Revest M, Veyer D, Essig M, Rerolles JP, Rawlinson W et al. Maribavir use in practice for cytomegalovirus infection in French transplantation centers. Transplant Proc. 2013; 45 (4): 1603–1607. doi: 10.1016/j.transproceed.2013.01.082.

119. Papanicolaou GA, Silveira FP, Langston AA, Pereira MR, Avery RK, Uknis M et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, Phase 2 study. Clin Infect Dis. 2018 Oct 16. doi: 10.1093/cid/ciy706.

120. Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017 21; 377 (25): 2433–2444. doi: 10.1056/NEJMoa1706640.

121. Kaul DR, Stoelben S, Cober E, Ojo T, Sandusky E, Lischka P et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011; 11 (5): 1079–1084. doi: 10.1111/j.16006143.2011.03530.x.

122. Stoelben S, Arns W, Renders L, Hummel J, Mühlfeld A, Stangl M et al. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Transpl Int. 2014; 27 (1): 77–86. doi: 10.1111/tri.12225.

123. Lugthart G, Albon SJ, Ricciardelli I, Kester MG, Meij P, Lankester AC, Amrolia PJ. Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy. J Immunother. 2012; 35 (1): 42–53. doi: 10.1097/CJI.0b013e31823569e2.

124. Gerdemann U, Katari UL, Papadopoulou A, Keirnan JM, Craddock JA, Liu H et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013; 21 (11): 2113–2121. doi: 10.1038/ mt.2013.151.

125. McVoy MA. Cytomegalovirus vaccines. Clin Infect Dis. 2013; 57 Suppl 4: S196–199. doi: 10.1093/cid/cit587.


Для цитирования:


Прокопенко Е.И. Цитомегаловирусная инфекция после трансплантации почки: реальные достижения и перспективы изучения патогенеза, профилактики и лечения. Вестник трансплантологии и искусственных органов. 2019;21(3):151-165. https://doi.org/10.15825/1995-1191-2019-3-151-165

For citation:


Prokopenko E.I. Cytomegalovirus infection after kidney transplantation: real progress and prospects for pathogenesis research, prevention and treatment. Russian Journal of Transplantology and Artificial Organs. 2019;21(3):151-165. (In Russ.) https://doi.org/10.15825/1995-1191-2019-3-151-165

Просмотров: 192


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-1191 (Print)
ISSN 2412-6160 (Online)